




RealRate

PHARMACEUTICAL 2016

Tonix Pharmaceuticals Holding Corp
Rank 163 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 3.0% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	46,359
Cost of Goods Sold	0
Intangible Assets	120
Liabilities, Current	6,650
Liabilities, Non-Current	0
Other Assets	189
Other Compr. Net Income	-19
Other Expenses	0
Other Liabilities	106
Other Net Income	108
Other Revenues	0
Property and Equipment	350
Research and Development	35,504
Selling, General and Administrative Expense	12,658

Output Variable	Value in 1000 USD
Assets	47,018
Liabilities	6,756
Expenses	48,162
Revenues	0
Stockholders Equity	40,262
Net Income	-48,054
Comprehensive Net Income	-48,064
BaseVar	51,032
ECR before LimitedLiability	148%
Economic Capital Ratio	266%